Cat. No.: HY-N0841

Bruceine A

(Synonyms: Dihydrobrusatol; NSC310616)

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

Bruceine A (Dihydrobrusatol) is a natural quassinoid. Bruceine A is an inhibitor of parasites, NF-κB, and PFKFB4 (K_d: 44 nM). Bruceine A is an activator of P38α MAPK. Bruceine A has antiparasitic activity. Bruceine A has antitumor activity and inhibits cancer cell migration. Bruceine A blocks the cell cycle and induces apoptosis. Bruceine A can be used in parasites, pancreatic cancer, and breast cancer research.

For research use only. We do not sell to patients.

Purity: 99.89%
CAS No.: 25514-31-2
Formula: C₂₆H₃₄O₁₁
Molecular Weight:522.54

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Bruceine A Chemical Structure

CAS No.: 25514-31-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

PFKFB4

44 nM (Kd)

All Parasite Isoforms :

All NF-κB Isoforms :

All p38 MAPK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	0.082 μM Compound: 9b	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by WST-1 assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by WST-1 assay	[PMID: 33289552]
HeLa	IC₅₀	1.1 μM Compound: 9b	Antiproliferative activity against human HeLa cells Antiproliferative activity against human HeLa cells	[PMID: 33289552]
HL-60	IC₅₀	0.13 μM Compound: 9b	Antiproliferative activity against human HL-60 cells Antiproliferative activity against human HL-60 cells	[PMID: 33289552]
HT-29	IC₅₀	3.1 μM Compound: 9b	Antiproliferative activity against human HT-29 cells Antiproliferative activity against human HT-29 cells	[PMID: 33289552]
LNCaP	ED₅₀	96 nM Compound: 7	Cytotoxicity against hormone-dependent human LNCAP cells after 2 days by sulforhodamine B assay Cytotoxicity against hormone-dependent human LNCAP cells after 2 days by sulforhodamine B assay	[PMID: 19026551]
Lu1	ED₅₀	79 nM Compound: 7	Cytotoxicity against human Lu1 cells after 2 days by sulforhodamine B assay Cytotoxicity against human Lu1 cells after 2 days by sulforhodamine B assay	[PMID: 19026551]
MCF7	ED₅₀	1.5 nM Compound: 7	Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay in presence of 43 uM (-)-hydnocarpin Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay in presence of 43 uM (-)-hydnocarpin	[PMID: 19026551]
MCF7	ED₅₀	15 nM Compound: 7	Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay	[PMID: 19026551]
MCF7	IC₅₀	0.18 μM Compound: 9b	Cytotoxicity against human MCF-7 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MCF-7 cells incubated for 72 hrs by MTT assay	[PMID: 33289552]
MDA-MB-231	IC₅₀	0.23 μM Compound: 9b	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 33289552]

In Vitro

Bruceine A (6.25-100 nM/0.08-20 μM, 24-72 h) inhibits the viability of pancreatic cancer cell lines MIA PaCa-2, SW1990, PANC-1 and AsPC-1 cells in a time- and dose-dependent manner^[1].
Bruceine A (12.5-50 nM, 24 h) increases the percentage of MIA PaCa-2 cells in the G1 phase^[1].
Bruceine A (12.5-50 nM, 24 h) induces apoptosis of MIA PaCa-2 cells in a dose-dependent manner^[1].
Bruceine A (12.5-50 nM, 24 h) inhibits the mRNA expression level of PFKFB4 in MIA PaCa-2 cells^[1].
Bruceine A (30-120 nM/0.3-1.2 μM, 24-48 h) inhibits the viability of MDA-MB-231 (IC₅₀: 78.4 nM) and 4T1 (IC₅₀: 524.6 nM) cells in triple negative breast cancer (TNBC) cell lines^[2].
Bruceine A (7.5-30 nM/150-450 nM, 48 h) causes G0-G1 cell cycle arrest in MDA-MB-231 and 4T1 cells^[2].
Bruceine A (60-240 nM/0.6-2.4 μM, 48 h) induces apoptosis (58.37% and 56.21%) in MDA-MB-231 and 4T1 cells in a dose-dependent manner^[2].
Bruceine A (30-120 nM/0.3-1.2 μM, 24 h) inhibits the migration of MDA-MB-231 and 4T1 cells in a concentration-dependent manner^[2].
Bruceine A (72 h) inhibits the activity of Entamoeba histolytica (IC₅₀: 222.0 nM), Plasmodium falciparum (IC₅₀: 21.0 nM), Babesia gibbsii (IC₅₀: 7.7 nM), and Trypanosoma evansi (IC₅₀: 2.9 nM)^[3].
Bruceine A (2 h) inhibits the activity of NF-κB in Hela cells (IC₅₀: 5.3 μg/mL)^[4].
Bruceine A activates the p38α MAPK signaling pathway in MIA PaCa-2 cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

MIA PaCa-2 cells; SW1990, PANC-1 and AsPC-1 cells
Concentration:

6.25, 12.5, 25, 50 and 100 nM; 0.08, 0.31, 1.25, 5 and 20 μM
Incubation Time:

24, 48 and 72 h
Result:

Inhibited the growth of adenocarcinoma cell lines MIA PaCa-2, SW1990, PANC-1, and AsPC-1 cells.

Western Blot Analysis^[1]

Cell Line:

MIA PaCa-2 cells
Concentration:

12.5, 25 and 50 nM
Incubation Time:

24 h
Result:

Down-regulated protein levels of CDK4, CDK6 and Cyclin D1.
Increased the expression of apoptosis-related proteins cleaved caspase3, cleaved caspase9, and cleaved PARP.

RT-PCR^[1]

Cell Line:

MIA PaCa-2 cells
Concentration:

12.5, 25 and 50 nM
Incubation Time:

24 h
Result:

Inhibited the mRNA expression level of PFKFB4 in MIA PaCa-2 cells.

Cell Viability Assay^[2]

Cell Line:

MDA-MB-231 and 4T1 cells
Concentration:

24 and 48 h
Incubation Time:

24, 48 and 72 h
Result:

Inhibits the proliferation activity of MDA-MB-231 and 4T1 cells.

Western Blot Analysis^[2]

Cell Line:

MDA-MB-231 and 4T1 cells
Concentration:

30, 60 and 120 nM; 0.3, 0.6 and 1.2 μM
Incubation Time:

24 h
Result:

Down-regulated the protein expression levels of CDK4, CDK6 and Cyclin D1.
Up-regulated the protein expression levels of Bax, Cyt C and Cleaved-Caspase-3/9.
Down-regulated the protein expression levels of Bcl-2, PARP and Caspase-3/9.
Down-regulated the protein expression levels of MMP2 and MMP9.

In Vivo

Bruceine A (0.02-0.5 mg/kg, i.v., once every day for 10 d) exhibits antitumor activity in mice with the BALB/c nude mouse pancreatic cancer model^[1]^[4].
Bruceine A (2-4 mg/kg, i.p., once every day for 2 weeks) has antitumor activity in mice with 4T1 xenograft tumor model^[2].
Bruceine A (2-4 mg/kg, i.p., once every day for 17 d) inhibits lung metastasis in mice with 4T1-luc breast cancer lung metastasis model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c athymic male nude mice pancreatic cancer model (6 weeks old)^[1]
Dosage:

0.02, 0.1, 0.5 mg/kg
Administration:

Intravenous injection (i.v.), once every day for 10 d
Result:

Inhibited tumor growth.
Reduced protein levels of PFKFB4 and GSK3β in tumor tissues.
Reduced PCNA and Ki67 positive cells.

Animal Model:

4T1 xenograft tumor model (female BALB/c mice, 6-8 weeks old, 18-20 g)^[2]
Dosage:

2 and 4 mg/kg
Administration:

Intraperitoneal injection (i.p.), once every day for 2 weeks
Result:

Inhibited tumor growth.
Reduced Ki67 proliferation marker staining and p-MEK staining.

Animal Model:

4T1-luc breast cancer lung metastasis model (female BALB/c mice, 6-8 weeks old, 18-20 g)^[2]
Dosage:

2 and 4 mg/kg
Administration:

Intraperitoneal injection (i.p.), once every day for 17 d
Result:

Inhibited lung metastasis.

Chemical Information

CAS No. 25514-31-2
Appearance Solid
Molecular Weight 522.54
Formula C₂₆H₃₄O₁₁
Color White to off-white
SMILES

O=C([C@@]1([C@H]([C@H](O)[C@]2([H])[C@]3(C4)C)O)[C@@]([C@H](C5=O)OC(CC(C)C)=O)([H])[C@@]2([C@@](O5)([H])C[C@@]3([H])C(C)=C(O)C4=O)CO1)OC
Synonyms

Dihydrobrusatol; NSC310616
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (3)

All

Sort by:

Journal Impact Factor

Nat Microbiol

Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2. [Abstract]

2023 Jan;8(1):121-134. PMID: 36604514
Biochem Pharmacol

Quassinoid analogs exert potent antitumor activity via reversible protein biosynthesis inhibition in human colorectal cancer. [Abstract]

2023 Jun:212:115564. PMID: 37116665
Chem Biol Drug Des

Bruceine A inhibited breast cancer proliferation and metastasis by inducing autophagy via targeting PI3K-AKT signaling pathway. [Abstract]

2024 Jan;103(1):e14398. PMID: 38010171

Solvent & Solubility

In Vitro:

DMSO : ≥ 25 mg/mL (47.84 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9137 mL

9.5686 mL

19.1373 mL

5 mM

0.3827 mL

1.9137 mL

3.8275 mL

10 mM

0.1914 mL

0.9569 mL

1.9137 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.98 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.98 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (289 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang P, et al. Bruceine A induces cell growth inhibition and apoptosis through PFKFB4/GSK3β signaling in pancreatic cancer. Pharmacol Res. 2021 Jul;169:105658. [Content Brief]

[2]. Li X, et al. Bruceine A: Suppressing metastasis via MEK/ERK pathway and invoking mitochondrial apoptosis in triple-negative breast cancer. Biomed Pharmacother. 2023 Dec;168:115784. [Content Brief]

[3]. Bawm S, et al. In vitro antitrypanosomal activities of quassinoid compounds from the fruits of a medicinal plant, Brucea javanica. Vet Parasitol. 2008 Dec 20;158(4):288-94. [Content Brief]

[4]. Kim JA, et al. NF-kappaB inhibitors from Brucea javanica exhibiting intracellular effects on reactive oxygen species. Anticancer Res. 2010 Sep;30(9):3295-300. [Content Brief]

[5]. Lu C, et al. A novel P38α MAPK activator Bruceine A exhibits potent anti-pancreatic cancer activity. Comput Struct Biotechnol J. 2021 Jun 6;19:3437-3450. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9137 mL	9.5686 mL	19.1373 mL	47.8432 mL
	5 mM	0.3827 mL	1.9137 mL	3.8275 mL	9.5686 mL
	10 mM	0.1914 mL	0.9569 mL	1.9137 mL	4.7843 mL
	15 mM	0.1276 mL	0.6379 mL	1.2758 mL	3.1895 mL
	20 mM	0.0957 mL	0.4784 mL	0.9569 mL	2.3922 mL
	25 mM	0.0765 mL	0.3827 mL	0.7655 mL	1.9137 mL
	30 mM	0.0638 mL	0.3190 mL	0.6379 mL	1.5948 mL
	40 mM	0.0478 mL	0.2392 mL	0.4784 mL	1.1961 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Bruceine A

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Terpenoids Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Phosphatase Inhibitor Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Bruceine A

All Parasite Isoforms

All NF-κB Isoforms

All p38 MAPK Isoforms

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Bruceine A Related Classifications

Cat. No.: HY-N0841